These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 34079622)

  • 1. Immunoregulation and antidepressant effect of ketamine.
    Zhang N; Yao L; Wang P; Liu Z
    Transl Neurosci; 2021 Jan; 12(1):218-236. PubMed ID: 34079622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ketamine as antidepressant? Current state and future perspectives.
    Hasselmann HW
    Curr Neuropharmacol; 2014 Jan; 12(1):57-70. PubMed ID: 24533016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective.
    Hashimoto K
    Psychiatry Clin Neurosci; 2019 Oct; 73(10):613-627. PubMed ID: 31215725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pro-inflammatory monocyte profile in patients with major depressive disorder and suicide behaviour and how ketamine induces anti-inflammatory M2 macrophages by NMDAR and mTOR.
    Nowak W; Grendas LN; Sanmarco LM; Estecho IG; Arena ÁR; Eberhardt N; Rodante DE; Aoki MP; Daray FM; Carrera Silva EA; Errasti AE
    EBioMedicine; 2019 Dec; 50():290-305. PubMed ID: 31753725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
    Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
    J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ketamine and Ro 25-6981 Reverse Behavioral Abnormalities in Rats Subjected to Dietary Zinc Restriction.
    Pochwat B; Domin H; Rafało-Ulińska A; Szewczyk B; Nowak G
    Int J Mol Sci; 2020 Jul; 21(13):. PubMed ID: 32640759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review.
    Iadarola ND; Niciu MJ; Richards EM; Vande Voort JL; Ballard ED; Lundin NB; Nugent AC; Machado-Vieira R; Zarate CA
    Ther Adv Chronic Dis; 2015 May; 6(3):97-114. PubMed ID: 25954495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current Status of Ketamine and Related Therapies for Mood and Anxiety Disorders.
    Costi S; Van Dam NT; Murrough JW
    Curr Behav Neurosci Rep; 2015 Dec; 2(4):216-225. PubMed ID: 26783510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ketamine and magnesium common pathway of antidepressant action.
    Górska N; Cubała WJ; Słupski J; Gałuszko-Węgielnik M
    Magnes Res; 2018 May; 31(2):33-38. PubMed ID: 30398153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retracing our steps to understand ketamine in depression: A focused review of hypothesized mechanisms of action.
    Irwin MN; VandenBerg A
    Ment Health Clin; 2021 May; 11(3):200-210. PubMed ID: 34026396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survey of NMDA Receptor-related Biomarkers for Depression.
    Chen YM; Lin CH; Lane HY
    Curr Pharm Des; 2020; 26(2):228-235. PubMed ID: 31969091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A brief history of the development of antidepressant drugs: from monoamines to glutamate.
    Hillhouse TM; Porter JH
    Exp Clin Psychopharmacol; 2015 Feb; 23(1):1-21. PubMed ID: 25643025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of the activity of
    Vasilescu AN; Schweinfurth N; Borgwardt S; Gass P; Lang UE; Inta D; Eckart S
    Neuropsychiatr Dis Treat; 2017; 13():973-980. PubMed ID: 28408831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder.
    Ghasemi M; Kazemi MH; Yoosefi A; Ghasemi A; Paragomi P; Amini H; Afzali MH
    Psychiatry Res; 2014 Feb; 215(2):355-61. PubMed ID: 24374115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of NMDA receptor in neurobiology and treatment of major depressive disorder: Evidence from translational research.
    Amidfar M; Woelfer M; Réus GZ; Quevedo J; Walter M; Kim YK
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Aug; 94():109668. PubMed ID: 31207274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnesium and ketamine in the treatment of depression.
    Górska N; Słupski J; Szałach ŁP; Włodarczyk A; Szarmach J; Jakuszkowiak-Wojten K; Gałuszko-Węgielnik M; Wilkowska A; Wiglusz MS; Cubała WJ
    Psychiatr Danub; 2019 Sep; 31(Suppl 3):549-553. PubMed ID: 31488789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antidepressant-like effects of ketamine in a mouse model of serotonergic dysfunction.
    Wilson C; Li S; Hannan AJ; Renoir T
    Neuropharmacology; 2020 May; 168():107998. PubMed ID: 32061666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NMDAR inhibition-independent antidepressant actions of ketamine metabolites.
    Zanos P; Moaddel R; Morris PJ; Georgiou P; Fischell J; Elmer GI; Alkondon M; Yuan P; Pribut HJ; Singh NS; Dossou KS; Fang Y; Huang XP; Mayo CL; Wainer IW; Albuquerque EX; Thompson SM; Thomas CJ; Zarate CA; Gould TD
    Nature; 2016 May; 533(7604):481-6. PubMed ID: 27144355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ketamine and other potential glutamate antidepressants.
    Dutta A; McKie S; Deakin JFW
    Psychiatry Res; 2015 Jan; 225(1-2):1-13. PubMed ID: 25467702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The promise of ketamine for treatment-resistant depression: current evidence and future directions.
    DeWilde KE; Levitch CF; Murrough JW; Mathew SJ; Iosifescu DV
    Ann N Y Acad Sci; 2015 May; 1345(1):47-58. PubMed ID: 25649308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.